Download
https://pipelinereview.com/nektar-therapeutics-and-bristol-myers-squibb-announce-u-s-fda-breakthrough-therapy-designation-for-bempegaldesleukin-nktr-214-in-combination-with-opdivo-nivolumab-for-the-treatment-of-patients-with-un/
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo® (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Share